candoxatril has been researched along with Cardiometabolic Syndrome in 1 studies
*Cardiometabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components not only include metabolic dysfunctions of METABOLIC SYNDROME but also HYPERTENSION, and ABDOMINAL OBESITY. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eizenberg, Y; Grossman, E; Peleg, E; Shabtai, Z; Sharabi, Y | 1 |
1 other study(ies) available for candoxatril and Cardiometabolic Syndrome
| Article | Year |
|---|---|
Neutral endopeptidase inhibitor versus angiotensin converting enzyme inhibitor in a rat model of the metabolic syndrome.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Disease Models, Animal; Enalapril; Indans; Insulin; Male; Metabolic Syndrome; Propionates; Rats; Rats, Sprague-Dawley; Triglycerides | 2014 |